CO2022014273A2 - Medicamentos para fibrosis pulmonar que contienen derivado de pirazol - Google Patents
Medicamentos para fibrosis pulmonar que contienen derivado de pirazolInfo
- Publication number
- CO2022014273A2 CO2022014273A2 CONC2022/0014273A CO2022014273A CO2022014273A2 CO 2022014273 A2 CO2022014273 A2 CO 2022014273A2 CO 2022014273 A CO2022014273 A CO 2022014273A CO 2022014273 A2 CO2022014273 A2 CO 2022014273A2
- Authority
- CO
- Colombia
- Prior art keywords
- pulmonary fibrosis
- medicines
- pyrazole derivative
- containing pyrazole
- fibrosis containing
- Prior art date
Links
- 208000005069 pulmonary fibrosis Diseases 0.000 title abstract 2
- 150000003217 pyrazoles Chemical class 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200044598 | 2020-04-13 | ||
| KR1020210036863A KR102386097B1 (ko) | 2020-04-13 | 2021-03-22 | 피라졸 유도체의 폐섬유증 치료제 |
| PCT/KR2021/003537 WO2021210799A1 (ko) | 2020-04-13 | 2021-03-23 | 피라졸 유도체의 폐섬유증 치료제 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022014273A2 true CO2022014273A2 (es) | 2022-10-21 |
Family
ID=78083982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0014273A CO2022014273A2 (es) | 2020-04-13 | 2022-10-05 | Medicamentos para fibrosis pulmonar que contienen derivado de pirazol |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12616684B2 (enExample) |
| EP (1) | EP4137134A4 (enExample) |
| JP (1) | JP7539485B2 (enExample) |
| KR (2) | KR102567012B1 (enExample) |
| CN (1) | CN115427039B (enExample) |
| AU (1) | AU2021255160B2 (enExample) |
| BR (1) | BR112022020649A2 (enExample) |
| CA (1) | CA3172596A1 (enExample) |
| CL (1) | CL2022002642A1 (enExample) |
| CO (1) | CO2022014273A2 (enExample) |
| MX (1) | MX2022012726A (enExample) |
| WO (1) | WO2021210799A1 (enExample) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040094464A (ko) * | 2003-05-02 | 2004-11-10 | 학교법인 이화학당 | 피리디닐 피라졸 유도체 |
| KR20120054077A (ko) | 2009-08-21 | 2012-05-29 | 길리아드 바이오로직스, 인크. | 폐 섬유증 장애의 치료를 위한 방법 및 조성물 |
| WO2011028043A2 (ko) | 2009-09-02 | 2011-03-10 | 이화여자대학교 산학협력단 | 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물 |
| KR101302315B1 (ko) * | 2011-07-19 | 2013-08-30 | 이화여자대학교 산학협력단 | 피라졸 유도체를 포함하는 호흡기 질환 예방 및 치료용 조성물 |
| KR101633957B1 (ko) | 2012-08-27 | 2016-06-27 | 이화여자대학교 산학협력단 | 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물 |
| US10548911B2 (en) * | 2014-06-16 | 2020-02-04 | University Of Rochester | Small molecule anti-scarring agents |
| US11096952B2 (en) * | 2016-02-02 | 2021-08-24 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Chemicals and methods to prevent and treat TGF-beta mediated activation of fibroblasts to reduce and treat cancer and fibrosis |
| WO2017192304A1 (en) | 2016-05-02 | 2017-11-09 | Inception 1, Inc. | Arylcarboxamides and uses thereof |
| CA3046158A1 (en) | 2017-01-27 | 2018-08-02 | Genfit | Pharmaceutical compositions for combination therapy |
| KR101821593B1 (ko) | 2017-02-23 | 2018-01-25 | 압타바이오 주식회사 | 안질환 치료제 |
| IL268751B (en) | 2017-03-13 | 2022-08-01 | Genfit | Pharmaceutical preparations for combined treatment |
| CN110536683A (zh) | 2017-04-18 | 2019-12-03 | 基恩菲特公司 | 包含PPAR激动剂如伊拉非诺和乙酰CoA羧化酶ACC抑制剂的组合 |
| KR101856444B1 (ko) | 2017-04-20 | 2018-05-10 | 압타바이오 주식회사 | 3-페닐-4-프로필-1-(피리딘-2-일)-1ｈ-피라졸-5-올 염산염의 신규 결정형 고체 화합물 |
| KR101840702B1 (ko) * | 2017-11-01 | 2018-03-22 | 압타바이오 주식회사 | 간질환 치료제 |
| TWI815938B (zh) | 2018-08-01 | 2023-09-21 | 日商日本化藥股份有限公司 | 具有n-烷基的芳香族胺樹脂、硬化性樹脂組成物及其硬化物 |
| EP3628669A1 (en) | 2018-09-28 | 2020-04-01 | GenKyoTex Suisse SA | Novel compounds as nadph oxidase inhibitors |
| KR102207340B1 (ko) | 2018-10-19 | 2021-01-22 | 한남대학교 산학협력단 | 표면 개질된 다공성 탄소복합소재 및 그 제조방법 |
| CN109912600B (zh) * | 2019-02-22 | 2021-08-03 | 四川大学华西医院 | 一种防治肺纤维化的咪唑并嘧啶类衍生物及其应用 |
| MX2022012472A (es) | 2020-04-08 | 2022-12-15 | Aptabio Therapeutics Inc | Agente para el tratamiento de lesion renal aguda inducida por medio de contraste. |
| WO2021263281A2 (en) * | 2020-06-26 | 2021-12-30 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Methods and compositions for the treatment of covid-19 and associated respiratory distress and multi-organ failure, sepsis, acute respiratory distress syndrome, and cordiovascular diseases |
| UY39671A (es) | 2021-03-15 | 2022-10-31 | Novartis Ag | Derivados de pirazolopiridina y sus usos. |
-
2021
- 2021-03-23 MX MX2022012726A patent/MX2022012726A/es unknown
- 2021-03-23 CN CN202180028319.3A patent/CN115427039B/zh active Active
- 2021-03-23 EP EP21787824.8A patent/EP4137134A4/en active Pending
- 2021-03-23 JP JP2022562440A patent/JP7539485B2/ja active Active
- 2021-03-23 CA CA3172596A patent/CA3172596A1/en active Pending
- 2021-03-23 AU AU2021255160A patent/AU2021255160B2/en active Active
- 2021-03-23 BR BR112022020649A patent/BR112022020649A2/pt unknown
- 2021-03-23 WO PCT/KR2021/003537 patent/WO2021210799A1/ko not_active Ceased
- 2021-03-23 US US17/918,497 patent/US12616684B2/en active Active
- 2021-11-24 KR KR1020210162964A patent/KR102567012B1/ko active Active
-
2022
- 2022-03-16 KR KR1020220032891A patent/KR20220039687A/ko active Pending
- 2022-09-27 CL CL2022002642A patent/CL2022002642A1/es unknown
- 2022-10-05 CO CONC2022/0014273A patent/CO2022014273A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021210799A1 (ko) | 2021-10-21 |
| JP7539485B2 (ja) | 2024-08-23 |
| KR20210146871A (ko) | 2021-12-06 |
| EP4137134A1 (en) | 2023-02-22 |
| US20230148365A1 (en) | 2023-05-11 |
| MX2022012726A (es) | 2022-11-07 |
| KR20220039687A (ko) | 2022-03-29 |
| CN115427039B (zh) | 2025-04-04 |
| BR112022020649A2 (pt) | 2022-11-29 |
| AU2021255160B2 (en) | 2024-02-01 |
| CA3172596A1 (en) | 2021-10-21 |
| JP2023522628A (ja) | 2023-05-31 |
| CL2022002642A1 (es) | 2023-06-16 |
| EP4137134A4 (en) | 2024-08-07 |
| KR102567012B1 (ko) | 2023-08-14 |
| AU2021255160A1 (en) | 2022-10-06 |
| US12616684B2 (en) | 2026-05-05 |
| CN115427039A (zh) | 2022-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220281A (es) | Derivados de pirazolilo útiles como agentes anti-cancerígenos | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| ECSP22071009A (es) | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead | |
| PY2240956A (es) | Nuevos Compuestos bicíclicos y sus usos | |
| MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
| CL2022003360A1 (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados (divisional de la solicitud 202002578) | |
| CO2026005655A2 (es) | Inhibidor de pan-kras y uso del mismo en medicinas | |
| CO2018005842A2 (es) | Composición farmacéutica que comprende un potente inhibidor de urat 1 | |
| UY37941A (es) | Derivados de bencimidazol y sus usos | |
| DOP2022000076A (es) | Inhibidores del factor d del complemento para administración oral | |
| CL2022002641A1 (es) | Agente para el tratamiento de lesión renal aguda inducida por medio de contraste | |
| CL2023000200A1 (es) | Nuevo derivado de pirazol | |
| CL2022001317A1 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma. | |
| AR114418A1 (es) | Compuesto cíclico de metilactama y su utilización farmacéutica | |
| CO2023006912A2 (es) | Nuevos derivados de indazol acetileno | |
| AR126892A1 (es) | Compuestos de aminopiridina sustituidos como inhibidores de egfr | |
| AR132764A1 (es) | Inhibidores de tyk2 y sus usos | |
| CU20200102A7 (es) | Compuestos derivados de isoindolin-1,2,4-triazol-3-carbonitrilo útiles para el tratamiento de enfermedades cinetoplastídicas | |
| MX2020011367A (es) | Compuesto oxo-sustituido. | |
| AR131735A1 (es) | Agentes terapéuticos | |
| MX2022016497A (es) | Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento, mejora o prevencion de la enfermedad fibrotica. | |
| CL2022002642A1 (es) | Medicamentos para fibrosis pulmonar que contienen derivado de pirazol | |
| UY37745A (es) | Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias | |
| AR126552A1 (es) | Composición farmacéutica para prevenir o tratar la esclerosis sistémica | |
| MX2024008745A (es) | Compuesto derivado de 1,3-benzodioxol y composicion farmaceutica que comprende el mismo. |